Cargando…

Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients

Poor response to tuberculosis (TB) therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharmacokinetic (PK) parameters can be affected by several factors, such as comorbidities or the interaction of TB drugs with food. This study aimed to determine the PK of isoniazid...

Descripción completa

Detalles Bibliográficos
Autores principales: Requena-Méndez, Ana, Davies, Geraint, Waterhouse, David, Ardrey, Alison, Jave, Oswaldo, López-Romero, Sonia Llanet, Ward, Stephen A., Moore, David A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249529/
https://www.ncbi.nlm.nih.gov/pubmed/25224007
http://dx.doi.org/10.1128/AAC.03258-14
_version_ 1782346862135607296
author Requena-Méndez, Ana
Davies, Geraint
Waterhouse, David
Ardrey, Alison
Jave, Oswaldo
López-Romero, Sonia Llanet
Ward, Stephen A.
Moore, David A. J.
author_facet Requena-Méndez, Ana
Davies, Geraint
Waterhouse, David
Ardrey, Alison
Jave, Oswaldo
López-Romero, Sonia Llanet
Ward, Stephen A.
Moore, David A. J.
author_sort Requena-Méndez, Ana
collection PubMed
description Poor response to tuberculosis (TB) therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharmacokinetic (PK) parameters can be affected by several factors, such as comorbidities or the interaction of TB drugs with food. This study aimed to determine the PK of isoniazid (INH) in a Peruvian TB population under observed daily and twice-weekly (i.e., biweekly) therapy. Isoniazid levels were analyzed at 2 and 6 h after drug intake using liquid chromatography mass spectrometric methods. A total of 107 recruited patients had available PK data; of these 107 patients, 42.1% received biweekly isoniazid. The mean biweekly dose (12.8 mg/kg of body weight/day) was significantly lower than the nominal dose of 15 mg/kg/day (P < 0.001), and this effect was particularly marked in patients with concurrent diabetes and in males. The median maximum plasma concentration (C(max)) and area under the concentration-time curve from 0 to 6 h (AUC(0–6)) were 2.77 mg/liter and 9.71 mg·h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg·h/liter, respectively, for biweekly administration. There were no differences in the C(max) with respect to gender, diabetes mellitus (DM) status, or HIV status. Food was weakly associated with lower levels of isoniazid during the continuation phase. Overall, 34% of patients during the intensive phase and 33.3% during the continuation phase did not reach the C(max) reference value. However, low levels of INH were not associated with poorer clinical outcomes. In our population, INH exposure was affected by weight-adjusted dose and by food, but comorbidities did not indicate any effect on PK. We were unable to demonstrate a clear relationship between the C(max) and treatment outcome in this data set. Twice-weekly weight-adjusted dosing of INH appears to be quite robust with respect to important potentially influential patient factors under program conditions.
format Online
Article
Text
id pubmed-4249529
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-42495292014-12-31 Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients Requena-Méndez, Ana Davies, Geraint Waterhouse, David Ardrey, Alison Jave, Oswaldo López-Romero, Sonia Llanet Ward, Stephen A. Moore, David A. J. Antimicrob Agents Chemother Pharmacology Poor response to tuberculosis (TB) therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharmacokinetic (PK) parameters can be affected by several factors, such as comorbidities or the interaction of TB drugs with food. This study aimed to determine the PK of isoniazid (INH) in a Peruvian TB population under observed daily and twice-weekly (i.e., biweekly) therapy. Isoniazid levels were analyzed at 2 and 6 h after drug intake using liquid chromatography mass spectrometric methods. A total of 107 recruited patients had available PK data; of these 107 patients, 42.1% received biweekly isoniazid. The mean biweekly dose (12.8 mg/kg of body weight/day) was significantly lower than the nominal dose of 15 mg/kg/day (P < 0.001), and this effect was particularly marked in patients with concurrent diabetes and in males. The median maximum plasma concentration (C(max)) and area under the concentration-time curve from 0 to 6 h (AUC(0–6)) were 2.77 mg/liter and 9.71 mg·h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg·h/liter, respectively, for biweekly administration. There were no differences in the C(max) with respect to gender, diabetes mellitus (DM) status, or HIV status. Food was weakly associated with lower levels of isoniazid during the continuation phase. Overall, 34% of patients during the intensive phase and 33.3% during the continuation phase did not reach the C(max) reference value. However, low levels of INH were not associated with poorer clinical outcomes. In our population, INH exposure was affected by weight-adjusted dose and by food, but comorbidities did not indicate any effect on PK. We were unable to demonstrate a clear relationship between the C(max) and treatment outcome in this data set. Twice-weekly weight-adjusted dosing of INH appears to be quite robust with respect to important potentially influential patient factors under program conditions. American Society for Microbiology 2014-12 /pmc/articles/PMC4249529/ /pubmed/25224007 http://dx.doi.org/10.1128/AAC.03258-14 Text en Copyright © 2014 Requena-Méndez et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license (http://creativecommons.org/licenses/by/3.0/) .
spellingShingle Pharmacology
Requena-Méndez, Ana
Davies, Geraint
Waterhouse, David
Ardrey, Alison
Jave, Oswaldo
López-Romero, Sonia Llanet
Ward, Stephen A.
Moore, David A. J.
Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title_full Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title_fullStr Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title_full_unstemmed Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title_short Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
title_sort effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in peruvian tuberculosis patients
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249529/
https://www.ncbi.nlm.nih.gov/pubmed/25224007
http://dx.doi.org/10.1128/AAC.03258-14
work_keys_str_mv AT requenamendezana effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT daviesgeraint effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT waterhousedavid effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT ardreyalison effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT javeoswaldo effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT lopezromerosoniallanet effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT wardstephena effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients
AT mooredavidaj effectsofdosagecomorbiditiesandfoodonisoniazidpharmacokineticsinperuviantuberculosispatients